Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada

,

doi:10.1097/qad.0000000000000941

Cited by 6 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[48,49] As a result, most studies indicate that individual ARVs and standard ART regimens are equally effective, regardless of HIV subtype. [50][51][52] In this study, the HIV-1-subtype and acquisition of HIVDRM were not significantly associated. In contrast, some studies showed that women and infants infected with HIV-subtype C were more likely to develop NVP resistance than other HIV subtypes.…”

Section: Discussioncontrasting

confidence: 61%

“…Antiretroviral drugs have generally proven to be effective against a wide range of HIV subtypes, despite being primarily tested in people with subtype B [48,49] . As a result, most studies indicate that individual ARVs and standard ART regimens are equally effective, regardless of HIV subtype [50–52] . In this study, the HIV-1-subtype and acquisition of HIVDRM were not significantly associated.…”

Section: Discussionmentioning

confidence: 58%

See 1 more Smart Citation

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya

et al. 2021

View full text Add to dashboard Cite

An estimated 1.5 million Kenyans are HIV-seropositive, with 1.1 million on antiretroviral therapy (ART), with the majority of them unaware of their drug resistance status. In this study, we assessed the prevalence of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs), nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors, and the variables associated with drug resistance in patients failing treatment in Nairobi, Kenya. This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017. The primary outcome was human immunodeficiency virus type 1 (HIV-1) drug resistance mutation counts determined by Sanger sequencing of the polymerase (pol) gene followed by interpretation using Stanford's HIV Drug Resistance Database. Poisson regression was used to determine the effects of sex, viral load, age, HIV-subtype, treatment duration, and ART-regimen on the primary outcome. HIV-1 drug resistance mutations were found in 82.3% of the subjects, with 15.3% of subjects having triple-class ART resistance and 45.2% having dual-class resistance. NRTI primary mutations M184 V/I and K65R/E/N were found in 28.8% and 8.9% of subjects respectively, while NNRTI primary mutations K103N/S, G190A, and Y181C were found in 21.0%, 14.6%, and 10.9% of subjects. We found statistically significant evidence ( P = .013) that the association between treatment duration and drug resistance mutations differed by sex. An increase of one natural-log transformed viral load unit was associated with 11% increase in drug resistance mutation counts (incidence rate ratio [IRR] 1.11; 95% CI 1.06–1.16; P < .001) after adjusting for age, HIV-1 subtype, and the sex-treatment duration interaction. Subjects who had been on treatment for 31 to 60 months had 63% higher resistance mutation counts (IRR 1.63; 95% CI 1.12–2.43; P = .013) compared to the reference group (<30 months). Similarly, patients on ART for 61 to 90 months were associated with 133% higher mutation counts than the reference group (IRR 2.33; 95% CI 1.59–3.49; P < .001). HIV-1 subtype, age, or ART-regimen were not associated with resistance mutation counts. Drug resistance mutations were found in alarmingly high numbers, and they were associated with viral load and treatment time. This finding emphasizes the importance of targeted resistance monitoring as a tool for addressing the problem.

show abstract

Section: Discussioncontrasting

confidence: 61%

Section: Discussionmentioning

confidence: 58%

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A relatively consistent finding is that compared with genotype A, genotype D is associated with mortality before ART 6 – 8 . Research on HIV-1 subtypes and ART showed that infection with genotype A results in increased mortality compared to that with genotype B in Europe and Canada 9 . In China, studies showed that CRF01_AE is associated with faster disease progression from estimated seroconversion to acquired immune deficiency syndrome (AIDS) compared with non-CRF01_AE in ART-naïve patients 10 , 11 .…”

Section: Introductionmentioning

confidence: 99%

Effects of HIV-1 genotype on baseline CD4+ cell count and mortality before and after antiretroviral therapy

Cao

Chen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

To assess whether human immunodeficiency virus type 1 (HIV-1) genotype influences baseline CD4+ T lymphocyte (CD4+) cell count and mortality of patients. The study was conducted from 2014 to 2019 in Guangxi, China, and included 2845 newly diagnosed HIV patients. We used a median regression model to compare CD4+ cell counts in patients newly diagnosed with different HIV-1 genotypes, and a Cox regression model to analyze the associations between HIV-1 genotypes and mortality before and after antiretroviral treatment (ART). In newly diagnosed HIV patients, the baseline CD4+ cell counts of patients with CRF01_AE were significantly lower than those of patients with CRF07_BC, CRF08_BC, and other genotypes. Compared with CRF01_AE, patients infected with CRF07_BC (hazard ratio, 0.55; 95% CI 0.36–0.85), CRF08_BC (hazard ratio, 0.67; 95% CI 0.52–0.85), or other genotypes (hazard ratio, 0.52; 95% CI 0.29–0.94) had significantly lower mortality rates before ART. There were no significant associations between different HIV-1 genotypes and mortality after ART. HIV-1 genotype significantly influences baseline CD4+ cell count and mortality before ART in newly diagnosed HIV patients. We find no significant difference in the outcome of death after ART in patients with different HIV-1 genotypes.

show abstract

“…Previous investigations have found that the distribution of HIV-1 subtype is correlated with infectious route and region. 2 In China, 47% CRF07_BC was concentrated in men who have sex with men. 20 Of all CRF08_BC, 67% were found in patients infected HIV through heterosexual contact and 23% through injecting drug use.…”

Section: Discussionmentioning

confidence: 99%

“… 1 Monitoring the subtype-specific differences in long-term clinical outcomes during ART can help reduce mortality. 2 – 4 Globally, the most prevalent HIV-1 subtype is C (46.6%), followed by B (12.1%), A (10.3%), CRF02_AG (7.7%), CRF01_AE (5.3%), G (4.6%), and D (2.7%). 5 A previous systematic review conducted in ART-naive patients suggested that HIV-1 subtypes C and D were the most aggressive in disease progression, followed by G, CRF01_AE, and CRF02_AG.…”

Section: Introductionmentioning

confidence: 99%

Impacts of HIV-1 Subtype Diversity on Long-Term Clinical Outcomes in Antiretroviral Therapy in Guangxi, China

Jiang

Lan

Zhu

et al. 2022

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada

Cited by 6 publications

References 43 publications

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya

Effects of HIV-1 genotype on baseline CD4+ cell count and mortality before and after antiretroviral therapy

Impacts of HIV-1 Subtype Diversity on Long-Term Clinical Outcomes in Antiretroviral Therapy in Guangxi, China

Contact Info

Product

Resources

About